Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up

Canadian Journal of Surgery

Volumn 57, Issue 1, 2014, Pages 26-32

  Simon, Renée ^a,b   Latreille, Jean ^a,b   Matte, Claire ^a,b   Desjardins, Pierre ^a,b   Bergeron, Eric ^a  

^a HÔPITAL CHARLES LEMOYNE   (Canada)

^b Centre Intégré de Cancérologie   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MASTECTOMY; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; STATISTICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEWS AS TOPIC; MASTECTOMY; MEDICATION ADHERENCE; MIDDLE AGED; QUALITATIVE RESEARCH; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84893868484     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: 10.1503/cjs.006211     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
2. Ries L A G, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2004. Bethesda (MD): National Cancer Institute; 2007.
3. Robertson J F R, Come SE, Jones SE, et al. Endocrine treatment options for advanced breast cancer - the role of fulvestrant. Eur J Cancer 2005;41:346-56.
4. Wyld L, Garg DK, Kumar ID, et al. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer 2004;90:1486-91.
5. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-9.
6. Winer E P, Hudis C, Bustein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptorpositive breast cancer. Stats report 2004. J Clin Oncol 2005;23:619-29.
7. Lin NU, Winer E P. Advances adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008;26:798-805.
8. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
9. Coombes RC, Hall E, Gibson LJ, et al. A randomozed trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
10. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal womenwith endocrine-responsive early-breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
11. Baum M, Buzdar AU, Cuzick J, et al.; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
12. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of five years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
13. Thürlimann B, Keshaviah A, Coates AS, et al. for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
14. Jakesz R, Jonat W, Grant M, et al.; ABCSG and GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after two years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
15. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23:5138-47.
16. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: update findings from NCIC CTG MA. 17. J Natl Cancer Inst 2005;97:1262-71.
17. Buzdar AU. Data from the arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res 2004;10:355S-61.
18. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. An overview of the randomized trials. Lancet 1998;351:1451-67.
19. Fisher B, Constantino JP, Wickerharn DL, et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
20. Barron TI, Connolly RM, Bennett K, et al. Early discontinuation of tamoxifen. A lesson for oncologists. Cancer 2007;109:832-9.
21. Markopoulos C, Polychronis A, Farfarelos C, et al. The effect of exemestane on the lipidemic profile of breast cancer patients. Preliminary results of the TEAM trial Greek sub-study. Breast Cancer Res Treat 2005;93:61-6.
22. Hutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of intergroup protocol INT-0102. J Clin Oncol 2005;23:8313-21.
23. Miaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer. A nursing perspective. Clin J Oncol Nurs 2008;12:213-21.
24. Ma AM, Barone J, Wallis AE, et al. Non compliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008;196:500-4.
25. Ruddy K, Mayer E, Partridge AH. Patients adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66.
26. Silliman RA, Guadagnoli E, Rakowski W, et al. Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 2002;20:2680-8.
27. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004;22:3309-15.
28. Demissie S, Silliman RA, Lash TL. Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19:322-8.
29. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963-70.
30. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42.
31. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancer of one centimetre or less. J Clin Oncol 2002;20:4141-9.
32. Partridge AH, La Fountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-62.
33. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6.
34. Grunfeld EA, Hunter MS, Sikka P, et al. Adherences beliefs among breast cancer patients taking tamoxifen. Patient Educ Counsel 1005;59:97-102.
35. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99:215-20.
36. Yen TW, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 2004;100:942-9.
37. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
38. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9.
39. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-3.
40. Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006;17:183-4.
41. Maurice A, Howell A, Evans DG, et al. Predicting compliance in a breast cancer prevention trial. Breast J 2006;12:446-50.
42. Ruddy KJ, Partridge AH. Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol 2009;20:401-2.
43. Stilley CS, Sereika S, Muldoon MF, et al. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-24.
44. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U. S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-9.
45. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-6.
46. Horne R, Weinman J. Patient's belief about prescribed medecines and their role in chronic physical illness. J Psychosom Res 1999;47:555-67.
47. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20:764-71.
48. Silliman RA, Troyan SL, Guadagnoli E, et al. The impact of age, marital status, and physician-patient interactions on the care of older women with breast cancer. Cancer 1997;80:1326-34.
49. Silliman RA, Demissie S, Troyan SL. The care of women with early stage breast cancer: What is the role of surgeon gender? Med Care 1999;37:1057-67.